All In Biotech

Drug Trial Radar · NCT04739761

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

506

Actual

Start

Jun 22, 2021

Primary completion

Feb 8, 2024

Study completion May 26, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Feb 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib).

Conditions

  • Breast Cancer

Interventions

  • Trastuzumab DeruxtecanDrug

    Participants will receive T-DXd administered using an IV bag containing 5% (w/v) dextrose injection infusion solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)Time frame: From first dose (Day 1) to progression of disease (up to 2 years 7 months)
  2. Progression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline)Time frame: At 12 months

Locations

81 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Boston, Massachusetts

  • Research Site

    Durham, North Carolina

  • Research Site

    Adelaide, Australia

  • Research Site

    Auchenflower, Australia

  • Research Site

    Clayton, Australia

  • Research Site

    Heidelberg, Australia

  • Research Site

    St Leonards, Australia

  • Research Site

    Subiaco, Australia

  • Research Site

    Anderlecht, Belgium

  • Research Site

    Bruges, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Copenhagen, Denmark

  • Research Site

    Herlev, Denmark

  • Research Site

    Odense C, Denmark

  • Research Site

    Helsinki, Finland

  • Research Site

    Tampere, Finland

  • Research Site

    Turku, Finland

  • Research Site

    Berlin, Germany

  • Research Site

    Dresden, Germany

  • Research Site

    Erlangen, Germany

  • Research Site

    Essen, Germany

  • Research Site

    Frankfurt, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Hanover, Germany

  • Research Site

    Kiel, Germany

  • Research Site

    Mannheim, Germany

  • Research Site

    München, Germany

  • Research Site

    München, Germany

  • Research Site

    Münster, Germany

  • Research Site

    Tübingen, Germany

  • Research Site

    Cork, Ireland

  • Research Site

    Dublin, Ireland

  • Research Site

    Dublin, Ireland

  • Research Site

    Ancona, Italy

  • Research Site

    Bergamo, Italy

  • Research Site

    Catania, Italy

  • Research Site

    Milan, Italy

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.